DK1152751T3 - Transdermalt, terapeutisk desoxypeganinsysstem - Google Patents

Transdermalt, terapeutisk desoxypeganinsysstem

Info

Publication number
DK1152751T3
DK1152751T3 DK00914071T DK00914071T DK1152751T3 DK 1152751 T3 DK1152751 T3 DK 1152751T3 DK 00914071 T DK00914071 T DK 00914071T DK 00914071 T DK00914071 T DK 00914071T DK 1152751 T3 DK1152751 T3 DK 1152751T3
Authority
DK
Denmark
Prior art keywords
desoxypeganine
weight percent
transdermal
deoxypeganine
therapeutic
Prior art date
Application number
DK00914071T
Other languages
Danish (da)
English (en)
Inventor
Thomas Hille
Lothar Deurer
Moormann Joachim Dr
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Application granted granted Critical
Publication of DK1152751T3 publication Critical patent/DK1152751T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
DK00914071T 1999-02-19 2000-02-08 Transdermalt, terapeutisk desoxypeganinsysstem DK1152751T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19906977A DE19906977C1 (de) 1999-02-19 1999-02-19 Desoxypeganin-TTS und seine Verwendung
PCT/EP2000/000971 WO2000048579A1 (de) 1999-02-19 2000-02-08 Desoxypeganin-tts

Publications (1)

Publication Number Publication Date
DK1152751T3 true DK1152751T3 (da) 2005-08-01

Family

ID=7898023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00914071T DK1152751T3 (da) 1999-02-19 2000-02-08 Transdermalt, terapeutisk desoxypeganinsysstem

Country Status (11)

Country Link
US (1) US6558696B1 (pt)
EP (1) EP1152751B1 (pt)
JP (1) JP2002537244A (pt)
KR (1) KR100674768B1 (pt)
AT (1) ATE293442T1 (pt)
AU (1) AU3551900A (pt)
DE (2) DE19906977C1 (pt)
DK (1) DK1152751T3 (pt)
ES (1) ES2241588T3 (pt)
PT (1) PT1152751E (pt)
WO (1) WO2000048579A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE10305137A1 (de) * 2003-02-07 2004-08-26 Novosis Ag Transdermale therapeutische Abgabesysteme mit einem Butenolid
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
US9084803B2 (en) 2007-06-29 2015-07-21 Board Of Trustees Of Northern Illinois University Therapeutic uses of glutathione mimics
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
KR101317158B1 (ko) 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
WO2020112766A1 (en) * 2018-11-26 2020-06-04 Steven Hoffman Compositions and methods for treating nerve agent exposure
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU605614A1 (ru) * 1971-10-20 1978-05-05 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср Антихолинэстеразное средство
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil

Also Published As

Publication number Publication date
EP1152751B1 (de) 2005-04-20
ATE293442T1 (de) 2005-05-15
DE19906977C1 (de) 2000-06-15
AU3551900A (en) 2000-09-04
WO2000048579A1 (de) 2000-08-24
KR20010102241A (ko) 2001-11-15
JP2002537244A (ja) 2002-11-05
ES2241588T3 (es) 2005-11-01
DE50010108D1 (de) 2005-05-25
KR100674768B1 (ko) 2007-01-25
EP1152751A1 (de) 2001-11-14
US6558696B1 (en) 2003-05-06
PT1152751E (pt) 2005-08-31

Similar Documents

Publication Publication Date Title
DE50010108D1 (de) Desoxypeganin-tts
BR0109107A (pt) Usos terapêuticos de mediadores ppar
MY109926A (en) Transdermal therapeutic system comprising galanthamine as active component
AU2961802A (en) Absorbing agents and cover layer which is impermeable to active substances and which contains channel-formers or removable protective layer of a transdermal therapeutic system
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
GB2174605A (en) Transdermal drug delivery
ATE342097T1 (de) Elektroaktive pore
EP1210050B8 (en) Diaper changing apparatus
MXPA03010295A (es) Sistema para administrar productos cosmeticos y farmaceuticos.
WO2002003969A3 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
BR9909486A (pt) Compostos calcilìticos
MXPA02009103A (es) Sistema terapeutico transdermal para la administracion de lerisetron.
ATE203906T1 (de) Zubereitung zur perkutanen verabreichung enthaltend 6-amino-5-chloro-1-isopropyl-2-(4- methyl-1-piperazinyl)benzimidazol
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
NO992674D0 (no) Konturen til et transdermalt terapeutisk system
DK0379933T3 (da) Superficielt behandlingssystem med indhold af et antineoplastisk aktivstof, især 5-fluoruracil
TW200719902A (en) Solid transdermal therapeutic system with uv absorber
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
ES2141548T3 (es) Preparado farmaceutico de superficie estabilizada para su aplicacion sobre la piel.
ES2188021T3 (es) Metodo para evitar el uso indebido de un sistema terapeutico percutaneo.
ATE252895T1 (de) Transdermales therapeutisches system und verfahren zu seiner herstellung
YU71293A (sh) Transdermalni terapijski sistem za davanje fizostigmina na koži i postupak za njegovu izradu